Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))
Articolo
Data di Pubblicazione:
2016
Citazione:
Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370)) / A. Armuzzi, P. Gionchetti, M. Daperno, S. Danese, A. Orlando, M.L. Scribano, M. Vecchi, F. Rizzello, S. Ardizzone, F. Castiglione, M. Fantini, G. Fiorino, G. Frieri, L. Neri, M. Principi, G.C. Sturniolo. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 48:9(2016 Sep), pp. 1103-1103. [10.1016/j.dld.2016.06.015]
Abstract:
In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Hepatology; Gastroenterology
Elenco autori:
A. Armuzzi, P. Gionchetti, M. Daperno, S. Danese, A. Orlando, M.L. Scribano, M. Vecchi, F. Rizzello, S. Ardizzone, F. Castiglione, M. Fantini, G. Fiorino, G. Frieri, L. Neri, M. Principi, G.C. Sturniolo
Link alla scheda completa: